Synergistic antibacterial effects of magnolia bark extract and L-arginine, N-α-lauroyl ethyl ester on plaque biofilm
US-10265367-B2 · Apr 23, 2019 · US
Compositions and methods for managing weight
US9844576B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9844576-B2 |
| Application number | US-201313904851-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 29, 2013 |
| Priority date | May 29, 2012 |
| Publication date | Dec 19, 2017 |
| Grant date | Dec 19, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides Diels-Alder adducts of chalcone and prenylphenyl moieties capable of modulating the activity of cannabinoid receptors, and to oligomers of flavan-3-ol capable of modulating fat absorption and storage. Such Diels-Alder adducts of chalcone and prenylphenyl moieties or oligomers of flavan-3-ol can optionally be used in combination with other weight management agents, such as anorectic agents, a lipase inhibitors, other cannabinoid receptor modulators, psychotropic agents, insulin sensitizers, stimulants, or satiety agents, as well as to methods of use thereof such as treating or preventing weight gain or obesity, promoting weight loss, appetite suppression, modifying satiety, or the like.
First claim
Opening claim text (preview).
We claim: 1. A tablet or capsule pharmaceutical or nutraceutical formulation, comprising a mixture of: a Morus alba extract with an increased amount of Albanin G, Kuwanon G, Morusin, or any combination thereof, as compared to the amount of Albanin G, Kuwanon G, Morusin, or any combination thereof in unextracted Morus alba ; a Magnolia officinalis extract with an increased amount of magnolol, honokiol, or both, as compared to the amount of magnolol, honokiol, or both in unextracted Magnolia officinalis; a Yerba Mate extract with an increased amount of caffeine, dicaffeoylquinic acid, or both as compared to the amount of caffeine, dicaffeoylquinic acid, or both in unextracted Yerba Mate; and a pharmaceutically or nutraceutically acceptable carrier, diluent, or excipient; wherein the tablet or capsule comprises about 0.5 weight percent (wt %) to about 90 wt % of active ingredients of the extract mixture.
Assignees
Inventors
Classifications
Antihyperlipidemics · CPC title
Anorexiants; Antiobesity agents · CPC title
Panax (ginseng) · CPC title
- A61K36/575Primary
Magnolia · CPC title
Piperaceae (Pepper family), e.g. Jamaican pepper or kava · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9844576B2 cover?
- The present disclosure provides Diels-Alder adducts of chalcone and prenylphenyl moieties capable of modulating the activity of cannabinoid receptors, and to oligomers of flavan-3-ol capable of modulating fat absorption and storage. Such Diels-Alder adducts of chalcone and prenylphenyl moieties or oligomers of flavan-3-ol can optionally be used in combination with other weight management agents…
- Who is the assignee on this patent?
- Unigen Inc, Unigen Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K36/575. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).